Monthly Round-Up of What to Read on Pharma Law and Policy
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from February 2022.

Interesting empirical studies, policy analyses, and editorials on health law and policy issues from February 2022.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from January 2022.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of November 2021.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of October 2021.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of August 2021.
Topics range from issues related to FDA’s approval of aducanumab, to an analysis of the communication of survival data in cancer drug labels.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of June 2021.
FDA’s approval of aducanumab may run against the bioethical principles of beneficence and non-maleficence.
Interesting empirical studies, policy analyses, and editorials on health law and policy issues from the month of May 2021.